The Cardiovascular Risk of Proton Pump Inhibitors and the Dangers of Polypharmacy. 

 -  2021 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>0025-6196 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Cardiovascular Diseases<br/>*Proton Pump Inhibitors<br/>Cardiovascular Diseases/ci [Chemically Induced]<br/>Cardiovascular Diseases/ep [Epidemiology]<br/>Heart Disease Risk Factors<br/>Humans<br/>Polypharmacy<br/>Proton Pump Inhibitors/ae [Adverse Effects]<br/>Risk Factors
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Heart & Vascular Institute<br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Cardiovascular Disease Fellowship
<br/><br/><label>Index Terms--Function: </label><br/>Editorial